Dr. Yun Kyoung Kang, Ph.D., is a highly accomplished professional with over 20 years of experience in basic research, spanning biochemistry, molecular biology, cell biology, and translational science, including drug discovery. Her expertise is complemented by a strategic, analytical, and creative mindset, as well as strong leadership skills.

Dr. Kang earned a Ph.D. in Biochemistry and Molecular Biology from The Rockefeller University in 2003, where she was mentored by Laskar Awardee Dr. Robert G. Roeder. She holds a B.S. in Molecular Biology from Seoul National University. Her academic appointments include roles as an adjunct professor at Hallym University and CHA Medical Science University. She also served as an assistant professor at the University of Florida and as an instructor and postdoctoral associate at Baylor College of Medicine. Her research interests lie in aging-associated diseases, such as metabolic disorders, cancers, and neurodegeneration.

Dr. Yun Kyoung Kang has held significant leadership roles in the pharmaceutical industry and startup ventures. As an executive officer at a pharmaceutical company, she was involved in global business development and strategic planning. Her notable achievements include successfully executing two out-licensing deals: the Lazertinib deal ($1.25 billion) to Janssen Biotech and the YH24931 deal to BridgeBio. She also has strong experience in developing R&D strategic roadmaps and supervising innovative drug pipelines.

Dr. Kang has been serving as the CEO of two startup companies, GAIABT and Y2K Global Innovation Lab.